Literature DB >> 24405619

Mortality following revision total knee arthroplasty: a matched cohort study of septic versus aseptic revisions.

Ho-Rim Choi1, Hany Bedair1.   

Abstract

We report the medium-term mortality after septic versus aseptic revision total knee arthroplasty (TKA) and factors that can contribute to mortality in revision TKA. Mortality rates of 88 patients undergoing septic revision (septic group) were compared with age- and year of surgery-matched 88 patients of aseptic revision (aseptic group). The overall mortality after revision TKA was 10.7% at a median of 4 years of follow-up (range, 2-7 years). However, the mortality after septic revision (18%, 16/88) was six times higher than that of aseptic revision (3%, 3/88) (P = 0.003). Infections with Staphylococcus aureus and/or methicillin resistance was not associated with higher mortality rates. Multivariate analysis indicated that increased age (P < 0.001), higher ASA class (P = 0.002), and septic revision (P < 0.001) were identified as independent predictors of increased mortality after revision TKA.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aseptic revision; longer-term; mortality; septic revision; total knee arthroplasty

Mesh:

Year:  2013        PMID: 24405619     DOI: 10.1016/j.arth.2013.11.026

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  16 in total

Review 1.  Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies.

Authors:  Mitchell C Birt; David W Anderson; E Bruce Toby; Jinxi Wang
Journal:  J Orthop       Date:  2016-10-26

2.  Early death following revision total knee arthroplasty.

Authors:  Mark D Jones; Michael Parry; Michael Whitehouse; Ashley W Blom
Journal:  J Orthop       Date:  2019-11-13

3.  A Multicenter Study of Irrigation and Debridement in Total Knee Arthroplasty Periprosthetic Joint Infection: Treatment Failure Is High.

Authors:  Kenneth L Urish; Andrew G Bullock; Alexander M Kreger; Neel B Shah; Kwonho Jeong; Scott D Rothenberger
Journal:  J Arthroplasty       Date:  2017-11-21       Impact factor: 4.757

4.  Viable bacteria persist on antibiotic spacers following two-stage revision for periprosthetic joint infection.

Authors:  Dongzhu Ma; Robert M Q Shanks; Charles M Davis; David W Craft; Thomas K Wood; Brian R Hamlin; Kenneth L Urish
Journal:  J Orthop Res       Date:  2017-06-28       Impact factor: 3.494

5.  A History of Treated Periprosthetic Joint Infection Increases the Risk of Subsequent Different Site Infection.

Authors:  Hany Bedair; Nitin Goyal; Mathew J Dietz; Kenneth Urish; Viktor Hansen; Jorge Manrique; William Hamilton; Greg Deirmengian
Journal:  Clin Orthop Relat Res       Date:  2015-07       Impact factor: 4.176

6.  Long-term outcomes of primary total knee arthroplasty in patients with hepatitis B virus infection.

Authors:  Ji-Hoon Baek; Su C Lee; Suengryol Ryu; Jin-Woo Kim; Chang H Nam
Journal:  Bone Jt Open       Date:  2022-06

7.  Benefits and Adverse Events Associated With Extended Antibiotic Use in Total Knee Arthroplasty Periprosthetic Joint Infection.

Authors:  Neel B Shah; Beverly L Hersh; Alex Kreger; Aatif Sayeed; Andrew G Bullock; Scott D Rothenberger; Brian Klatt; Brian Hamlin; Kenneth L Urish
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

8.  Survival, functional outcome and satisfaction of first revision total knee arthroplasty at a mean eleven-year follow-up.

Authors:  Andreas Hecker; Hans-Jürg A Pütz; Sebastian Wangler; Frank M Klenke
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-01-18

9.  Defining the minimal clinically important difference for the knee society score following revision total knee arthroplasty.

Authors:  Yong Zhi Khow; Ming Han Lincoln Liow; Graham S Goh; Jerry Yongqiang Chen; Ngai Nung Lo; Seng Jin Yeo
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-06-11       Impact factor: 4.114

Review 10.  Bisphosphonates for delivering drugs to bone.

Authors:  Shuting Sun; Jianguo Tao; Parish P Sedghizadeh; Philip Cherian; Adam F Junka; Esmat Sodagar; Lianping Xing; Robert K Boeckman; Venkatesan Srinivasan; Zhenqiang Yao; Brendan F Boyce; Brea Lipe; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino
Journal:  Br J Pharmacol       Date:  2021-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.